Show simple item record

dc.contributor.authorBernatz, Simonen_US
dc.contributor.authorIlina, Elena I.en_US
dc.contributor.authorDevraj, Kavien_US
dc.contributor.authorHarter, Patrick N.en_US
dc.contributor.authorMueller, Klausen_US
dc.contributor.authorKleber, Saschaen_US
dc.contributor.authorBraun, Yannicken_US
dc.contributor.authorPenski, Corneliaen_US
dc.contributor.authorRenner, Christophen_US
dc.contributor.authorHalder, Rashien_US
dc.contributor.authorJennewein, Lukasen_US
dc.contributor.authorSolbach, Christineen_US
dc.contributor.authorThorsen, Fritsen_US
dc.contributor.authorPestalozzi, Bernhard C.en_US
dc.contributor.authorMischo, Axelen_US
dc.contributor.authorMittelbronn, Michaelen_US
dc.PublishedBernatz S, Ilina, Devraj, Harter PN, Mueller K, Kleber, Braun Y, Penski, Renner, Halder, Jennewein, Solbach, Thorsen F, Pestalozzi, Mischo, Mittelbronn. Impact of Docetaxel on blood-brain barrier function and formation of breast cancer brain metastases. Journal of Experimental & Clinical Cancer Research. 2019;38:434eng
dc.description.abstractBackground: Breast cancer (BC) is the most frequent malignant tumor in females and the 2nd most common cause of brain metastasis (BM), that are associated with a fatal prognosis. The increasing incidence from 10% up to 40% is due to more effective treatments of extracerebral sites with improved prognosis and increasing use of MRI in diagnostics. A frequently administered, potent chemotherapeutic group of drugs for BC treatment are taxanes usually used in the adjuvant and metastatic setting, which, however, have been suspected to be associated with a higher incidence of BM. The aim of our study was to experimentally analyze the impact of the taxane docetaxel (DTX) on brain metastasis formation, and to elucidate the underlying molecular mechanism. Methods: A monocentric patient cohort was analyzed to determine the association of taxane treatment and BM formation. To identify the specific impact of DTX, a murine brain metastatic model upon intracardial injection of breast cancer cells was conducted. To approach the functional mechanism, dynamic contrast-enhanced MRI and electron microscopy of mice as well as in-vitro transendothelial electrical resistance (TEER) and tracer permeability assays using brain endothelial cells (EC) were carried out. PCR-based, immunohistochemical and immunoblotting analyses with additional RNA sequencing of murine and human ECs were performed to explore the molecular mechanisms by DTX treatment. Results: Taxane treatment was associated with an increased rate of BM formation in the patient cohort and the murine metastatic model. Functional studies did not show unequivocal alterations of blood-brain barrier properties upon DTX treatment in-vivo, but in-vitro assays revealed a temporary DTX-related barrier disruption. We found disturbance of tubulin structure and upregulation of tight junction marker claudin-5 in ECs. Furthermore, upregulation of several members of the tubulin family and downregulation of tetraspanin-2 in both, murine and human ECs, was induced. Conclusion: In summary, a higher incidence of BM was associated with prior taxane treatment in both a patient cohort and a murine mouse model. We could identify tubulin family members and tetraspanin-2 as potential contributors for the destabilization of the blood-brain barrier. Further analyses are needed to decipher the exact role of those alterations on tumor metastatic processes in the brain.en_US
dc.publisherBioMed Centraleng
dc.rightsAttribution CC BYeng
dc.titleImpact of Docetaxel on blood-brain barrier function and formation of breast cancer brain metastasesen_US
dc.typePeer reviewed
dc.typeJournal article
dc.rights.holderCopyright 2019 The Authors
dc.source.journalJournal of Experimental & Clinical Cancer Research

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution CC BY
Except where otherwise noted, this item's license is described as Attribution CC BY